Terms: = Germ cell tumor AND FGFR1, CEK, 2260, ENSG00000077782, P11362, FLT2, CD331, H3, HBGFR, FGFBR, H5, KAL2, H2, BFGFR, N-SAM, H4 AND Treatment
536 results:
1. RAPID resistance to BET inhibitors is mediated by fgfr1 in glioblastoma.
Jermakowicz AM; Kurimchak AM; Johnson KJ; Bourgain-Guglielmetti F; Kaeppeli S; Affer M; Pradhyumnan H; Suter RK; Walters W; Cepero M; Duncan JS; Ayad NG
Sci Rep; 2024 Apr; 14(1):9284. PubMed ID: 38654040
[TBL] [Abstract] [Full Text] [Related]
2. Identification of genetic modifiers enhancing B7-H3-targeting CAR T cell therapy against glioblastoma through large-scale CRISPRi screening.
Li X; Sun S; Zhang W; Liang Z; Fang Y; Sun T; Wan Y; Ma X; Zhang S; Xu Y; Tian R
J Exp Clin Cancer Res; 2024 Apr; 43(1):95. PubMed ID: 38561797
[TBL] [Abstract] [Full Text] [Related]
3. Focused ultrasound-mediated blood-brain barrier opening is safe and feasible with moderately hypofractionated radiotherapy for brainstem diffuse midline glioma.
Tazhibi M; McQuillan N; Wei HJ; Gallitto M; Bendau E; Webster Carrion A; Berg X; Kokossis D; Zhang X; Zhang Z; Jan CI; Mintz A; Gartrell RD; Syed HR; Fonseca A; Pavisic J; Szalontay L; Konofagou EE; Zacharoulis S; Wu CC
J Transl Med; 2024 Mar; 22(1):320. PubMed ID: 38555449
[TBL] [Abstract] [Full Text] [Related]
4. Immunohistochemical expression of histone modification pattern in adult glioblastoma.
Archana B; D'Cruze L; Sundaram S; Ramanathan K; Ganesh K
J Cancer Res Ther; 2024 Jan; 20(1):52-56. PubMed ID: 38554298
[TBL] [Abstract] [Full Text] [Related]
5. Bone Morphogenic Proteins in Pediatric Diffuse Midline Gliomas: How to Make New Out of Old?
Berthelot C; Huchedé P; Bertrand-Chapel A; Beuriat PA; Leblond P; Castets M
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542334
[TBL] [Abstract] [Full Text] [Related]
6. Identification of TMZ resistance-associated histone post-translational modifications in glioblastoma using multi-omics data.
Ye L; Gu L; Wang Y; Xing H; Li P; Guo X; Wang Y; Ma W
CNS Neurosci Ther; 2024 Mar; 30(3):e14649. PubMed ID: 38448295
[TBL] [Abstract] [Full Text] [Related]
7. OTUD4 promotes the progression of glioblastoma by deubiquitinating CDK1 and activating MAPK signaling pathway.
Ci M; Zhao G; Li C; Liu R; Hu X; Pan J; Shen Y; Zhang G; Li Y; Zhang L; Liang P; Cui H
Cell Death Dis; 2024 Mar; 15(3):179. PubMed ID: 38429268
[TBL] [Abstract] [Full Text] [Related]
8. Distant recurrence in the cerebellar dentate nucleus through the dentato-rubro-thalamo-cortical pathway in supratentorial glioma cases.
Kanamori M; Morishita Y; Shimoda Y; Yamamori E; Sato S; Osada Y; Osawa SI; Shibahara I; Saito R; Sonoda Y; Kumabe T; Endo H
Acta Neurochir (Wien); 2024 Feb; 166(1):83. PubMed ID: 38353806
[TBL] [Abstract] [Full Text] [Related]
9. ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma.
Arrillaga-Romany I; Gardner SL; Odia Y; Aguilera D; Allen JE; Batchelor T; Butowski N; Chen C; Cloughesy T; Cluster A; de Groot J; Dixit KS; Graber JJ; Haggiagi AM; Harrison RA; Kheradpour A; Kilburn LB; Kurz SC; Lu G; MacDonald TJ; Mehta M; Melemed AS; Nghiemphu PL; Ramage SC; Shonka N; Sumrall A; Tarapore RS; Taylor L; Umemura Y; Wen PY
J Clin Oncol; 2024 May; 42(13):1542-1552. PubMed ID: 38335473
[TBL] [Abstract] [Full Text] [Related]
10. Targeted therapies in retinoblastoma: GD2-directed immunotherapy following autologous stem cell transplantation and evaluation of alternative target B7-H3.
Eichholz T; Heubach F; Arendt AM; Seitz C; Brecht IB; Ebinger M; Flaadt T; Süsskind D; Richter L; Hülsenbeck I; Zerweck L; Göricke S; Paulsen F; Dombrowski F; Flotho C; Schönberger S; Ketteler P; Schulte J; Lang P
Cancer Immunol Immunother; 2024 Jan; 73(1):19. PubMed ID: 38240863
[TBL] [Abstract] [Full Text] [Related]
11. Feasibility and antitumour activity of the FGFR inhibitor erdafitnib in three paediatric CNS tumour patients.
Stepien N; Mayr L; Schmook MT; Raimann A; Dorfer C; Peyrl A; Azizi AA; Schramm K; Haberler C; Gojo J
Pediatr Blood Cancer; 2024 Mar; 71(3):e30836. PubMed ID: 38177074
[TBL] [Abstract] [Full Text] [Related]
12. Cortical myelin and thickness mapping provide insights into whole-brain tumor burden in diffuse midline glioma.
Zhang S; Yang X; Tan Q; Sun H; Chen D; Chen Y; Zhang H; Yang Y; Gong Q; Yue Q
Cereb Cortex; 2024 Jan; 34(1):. PubMed ID: 38112602
[TBL] [Abstract] [Full Text] [Related]
13. Differentiated neuroblastoma cells remain epigenetically poised for de-differentiation to an immature state.
Guyer RA; Picard N; Mueller JL; Ohishi K; Leavitt A; Murphy AJ; Cornejo KM; Hotta R; Goldstein AM
Dis Model Mech; 2023 Dec; 16(12):. PubMed ID: 38095019
[TBL] [Abstract] [Full Text] [Related]
14. Histone demethylase KDM4B accelerates the progression of glioblastoma via the epigenetic regulation of MYC stability.
Wang Z; Cai H; Li Z; Sun W; Zhao E; Cui H
Clin Epigenetics; 2023 Dec; 15(1):192. PubMed ID: 38093312
[TBL] [Abstract] [Full Text] [Related]
15. Immunohistochemistry Detection of Histone H3 K27M Mutation in Human Glioma Tissue.
Tarapore RS; Arain S; Blaine E; Hsiung A; Melemed AS; Allen JE
Appl Immunohistochem Mol Morphol; 2024 Feb; 32(2):96-101. PubMed ID: 38073235
[TBL] [Abstract] [Full Text] [Related]
16. Neuroblastoma: an ongoing cold front for cancer immunotherapy.
Kennedy PT; Zannoupa D; Son MH; Dahal LN; Woolley JF
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37993280
[TBL] [Abstract] [Full Text] [Related]
17. The iron chelator and OXPHOS inhibitor VLX600 induces mitophagy and an autophagy-dependent type of cell death in glioblastoma cells.
Reisbeck L; Linder B; Tascher G; Bozkurt S; Weber KJ; Herold-Mende C; van Wijk SJL; Marschalek R; Schaefer L; Münch C; Kögel D
Am J Physiol Cell Physiol; 2023 Dec; 325(6):C1451-C1469. PubMed ID: 37899749
[TBL] [Abstract] [Full Text] [Related]
18. Bench-to-bedside investigations of H3 K27-altered diffuse midline glioma: drug targets and potential pharmacotherapies.
Rechberger JS; Bouchal SM; Power EA; Nonnenbroich LF; Nesvick CL; Daniels DJ
Expert Opin Ther Targets; 2023; 27(11):1071-1086. PubMed ID: 37897190
[TBL] [Abstract] [Full Text] [Related]
19. Systematic characterization of antibody-drug conjugate targets in central nervous system tumors.
Coy S; Lee JS; Chan SJ; Woo T; Jones J; Alexandrescu S; Wen PY; Sorger PK; Ligon KL; Santagata S
Neuro Oncol; 2024 Mar; 26(3):458-472. PubMed ID: 37870091
[TBL] [Abstract] [Full Text] [Related]
20. Repurposing disulfiram, an alcohol-abuse drug, in neuroblastoma causes KAT2A downregulation and in vivo activity with a water/oil emulsion.
Beaudry A; Jacques-Ricard S; Darracq A; Sgarioto N; Garcia A; García TR; Lemieux W; Béland K; Haddad E; Cordeiro P; Duval M; McGraw S; Richer C; Caron M; Marois F; St-Onge P; Sinnett D; Banquy X; Raynal NJ
Sci Rep; 2023 Sep; 13(1):16443. PubMed ID: 37777587
[TBL] [Abstract] [Full Text] [Related]
[Next]
